Zacks Investment Research Downgrades American Renal Associates (ARA) to Hold

American Renal Associates (NYSE:ARA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Other research analysts have also issued research reports about the stock. SunTrust Banks restated a “buy” rating and set a $16.00 target price on shares of American Renal Associates in a research report on Wednesday, January 9th. Morgan Stanley began coverage on American Renal Associates in a research note on Friday, December 14th. They set an “equal weight” rating for the company. Deutsche Bank initiated coverage on American Renal Associates in a research report on Thursday, January 3rd. They set a “hold” rating and a $12.00 price target on the stock. ValuEngine cut American Renal Associates from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th. Finally, Barclays initiated coverage on American Renal Associates in a research report on Friday, December 14th. They set an “equal weight” rating and a $18.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $17.86.

American Renal Associates stock opened at $11.91 on Tuesday. The company has a debt-to-equity ratio of 5.48, a current ratio of 1.03 and a quick ratio of 1.00. The stock has a market cap of $382.08 million, a P/E ratio of 19.52, a PEG ratio of 3.19 and a beta of 2.13. American Renal Associates has a 52 week low of $11.09 and a 52 week high of $24.07.

A number of large investors have recently added to or reduced their stakes in ARA. Bank of New York Mellon Corp grew its position in American Renal Associates by 11.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 52,733 shares of the company’s stock valued at $831,000 after acquiring an additional 5,478 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in American Renal Associates by 28.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 71,327 shares of the company’s stock worth $1,125,000 after buying an additional 15,675 shares in the last quarter. BlackRock Inc. grew its holdings in shares of American Renal Associates by 33.2% in the 2nd quarter. BlackRock Inc. now owns 816,103 shares of the company’s stock valued at $12,869,000 after acquiring an additional 203,211 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in American Renal Associates by 94.3% in the second quarter. Dimensional Fund Advisors LP now owns 495,708 shares of the company’s stock valued at $7,818,000 after acquiring an additional 240,542 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of American Renal Associates by 69.9% during the second quarter. Bank of America Corp DE now owns 113,109 shares of the company’s stock valued at $1,784,000 after purchasing an additional 46,522 shares during the period. 94.42% of the stock is owned by institutional investors.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Article: Municipal Bonds

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit